• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

    2/13/24 4:05:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANEB alert in real time by email

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2023, and recent updates.

    Second Quarter Fiscal Year 2024 and Subsequent Highlights:

    • Richie Cunningham announced as Chief Executive Officer
    • United States Adopted Names (USAN) adopted selonabant as the generic name for ANEB-001
    • Advancing selonabant IV formulation as a second product
    • Secured a credit facility of up to $10 million
    • Bimal Shah announced as Board Member

    "Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication. Our current efforts are focused on completion of critical steps needed to support the future Phase 3 studies of selonabant, including efficient scale up of manufacturing, completion of remaining nonclinical activities, and finalizing the designs of our proposed registrational studies for further discussion with the FDA. One important development at Anebulo is the advancement of a selonabant IV formulation, which we are currently scaling-up for initial clinical safety studies as a potential treatment for patients where oral dosing is not an option, such as younger pediatric patients accidentally exposed to cannabis, who may experience serious outcomes like CNS depression, seizures, or coma," commented Richie Cunningham, Chief Executive Officer of Anebulo.

    "We find ourselves at a seminal moment to deliver a meaningfully constructive solution to healthcare providers and to their patients suffering with ACI and associated cannabis toxicities," Cunningham continued. "Despite the high tolerability of cannabis in the majority of users, a significant number of users who develop ACI may experience moderate to severe neuropsychiatric symptoms such as anxiety, paranoia, and psychosis. In addition to poor patient outcomes, cannabis toxicity places a substantial burden on the healthcare system.

    "We are pleased to report that the USAN Council has adopted selonabant as the generic name for ANEB-001. This is just another step in the journey to delivering a much needed solution to patients.

    "Lastly, the company has recently strengthened its capital structure by executing a credit facility with certain existing investors that will allow us access of up to $10 million. This facility reflects their on-going confidence and support as we continue to prepare for Phase 3 trials, a very important step in our mission."

    Financial Results for the three months ended December 31, 2023

    • Operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.
    • Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
    • Cash was $6.6 million as of December 31, 2023.

    About Selonabant (ANEB-001)

    Our lead product candidate is selonabant (ANEB-001), a potent, small molecule antagonist of cannabinoid receptor type 1 (CB1), under development to address the unmet medical need for a specific antidote for cannabis toxicity, including ACI. Selonabant is an orally bioavailable, readily absorbed treatment candidate that we anticipate will rapidly reverse key symptoms of ACI. Selonabant is protected by two issued patents and rights to four pending patent applications covering various methods of use of the compound and delivery systems. We are targeting initiation of Phase 3 registrational studies of oral selonabant in the first half of calendar 2024. In addition, an observational study in patients presenting to Emergency Departments with ACI is currently ongoing. The study will determine concentrations of cannabinoids and metabolites in plasma and gather information on signs and symptoms, patients' disposition and selected subjective assessments.

    About Anebulo Pharmaceuticals, Inc.

    Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and, longer term, for substance use disorders. Its lead product candidate, selonabant, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. Selonabant is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.

    Forward-Looking Statements

    Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as "anticipate," "designed," "expect," "may," "will," "should" and other comparable terms. Forward-looking statements include statements regarding Anebulo's intentions, beliefs, projections, outlook, analyses or current expectations regarding: the targeted commencement of phase 3 registrational trials for selonabant in the first half of calendar 2024; the advancement of a selonabant IV formulation; the observational study of selonabant; pending patent applications; the potential for selonabant to address an unmet medical need for a specific antidote for ACI; Anebulo becoming the first company to have an approved treatment for ACI; and Anebulo's expectation that selonabant will rapidly reverse key symptoms of ACI or related cannabis toxicities . You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: initial and interim results from clinical studies are not necessarily indicative of results that may be observed in the future; the ability to obtain regulatory approval; the timing and success of development efforts and clinical trials may be impacted by various factors, including safety and other complications; any negative effects on the Company's business and product development plans caused by or associated with health crises or geopolitical issues; and Anebulo's need for additional capital. These and other risks are described under the "Risk Factors" heading of Anebulo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed with the SEC on November 14, 2023, and in Anebulo's Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, being filed with the SEC on February 13, 2024. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.

    Condensed Balance Sheets

     

     

     

    December 31,

     

    June 30,

     

     

    2023

     

    2023

    Cash

     

    $

    6,644,517

     

     

    $

    11,247,403

     

    Total assets

     

     

    7,500,773

     

     

     

    11,670,151

     

    Total liabilities

     

     

    1,013,556

     

     

     

    1,068,801

     

    Total stockholders' equity

     

     

    6,487,217

     

     

     

    10,601,350

     

     

    Condensed Statements of Operations

     

     

     

    Three Months Ended December 31,

     

     

    2023

     

    2022

    Research and development

     

    $

    1,062,672

     

     

    $

    1,869,920

     

    General and administrative

     

     

    1,697,787

     

     

     

    1,943,202

     

    Total operating expenses

     

     

    2,760,459

     

     

     

    3,813,122

     

    Loss from operations

     

     

    (2,760,459

    )

     

     

    (3,813,122

    )

    Other (income) expenses:

     

     

     

     

     

     

     

     

    Interest income

     

     

    (75,522

    )

     

     

    (8,816)

     

    Other

     

     

    32,432

     

     

     

    22,646

     

    Total other (income) expenses, net

     

     

    (43,090

    )

     

     

    13,830

     

    Net loss

     

    $

    (2,717,369

    )

     

    $

    (3,826,952

    )

    Weighted average common shares outstanding, basic and diluted

     

     

    25,789,739

     

     

     

    25,633,217

     

    Net loss per share, basic and diluted

     

    $

    (0.11

    )

     

    $

    (0.15

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240213596703/en/

    Get the next $ANEB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANEB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANEB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      12/26/24 4:15:08 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing. FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediat

      2/14/25 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children Anebu

      12/23/24 9:15:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2024, and recent updates. First Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo announced it has been awarded the first tranche of a two-year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), under award number 1U01DA059995-01. With the support of NIDA, Anebulo aims to complete IND-enabling

      11/13/24 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lawler Joseph F.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:39 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shah Bimal R.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Cundy Kenneth C

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:37 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Leadership Updates

    Live Leadership Updates

    See more

    $ANEB
    SEC Filings

    See more
    • Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

      10/6/23 4:06:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

      Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

      3/8/23 8:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

      11/1/22 4:00:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/15/25 4:15:33 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/11/25 7:04:26 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/4/25 6:09:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANEB
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Third Quarter 2023 Financial Results

      Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

      11/8/23 4:01:00 PM ET
      $AMGN
      $ANEB
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Reports First Quarter 2023 Financial Results

      2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

      5/4/23 4:01:00 PM ET
      $ANEB
      $LGND
      $NOVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

      Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

      7/5/22 6:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care